Renalytix PLC Result of General Meeting
23 April 2024 - 1:09AM
RNS Regulatory News
RNS Number : 5653L
Renalytix PLC
22 April 2024
Renalytix plc
("Renalytix" or the
"Company")
Result of General
Meeting
LONDON and
SALT LAKE CITY, 22 April 2024 -
Renalytix plc
(NASDAQ: RNLX) (LSE: RENX) announces that at the
General Meeting ("GM") held
earlier today all resolutions were passed. Further
details of each of the resolutions are set out in Proxy Statement
that contains the Notice of General Meeting, which was sent to
shareholders on 3 April 2024.
The results of the GM are detailed below:
Resolution
|
|
Votes in favour
|
%
|
|
Votes against
|
%
|
|
Votes withheld
|
|
|
|
|
|
|
|
|
|
Resolution 1
|
|
50,091,780
|
98.77%
|
|
621,329
|
1.23%
|
|
120,431
|
Resolution 2
|
|
45,880,130
|
90.47%
|
|
4,832,979
|
9.53%
|
|
120,431
|
Resolution 3
|
|
50,072,092
|
98.74%
|
|
641,404
|
1.26%
|
|
120,044
|
Resolution 4
|
|
45,853,622
|
90.42%
|
|
4,859,914
|
9.58%
|
|
120,004
|
For further information, please
contact:
Renalytix
plc
James McCullough, CEO
|
www.renalytix.com
Via Walbrook PR
|
|
|
Stifel
(Nominated Adviser to the Company)
Nicholas Moore / Alex Price / Nick Harland /
Samira Essebiya / Harry Billen
|
Tel: 02077107600
|
|
|
Investec Bank
plc
Gary Clarence / Shalin Bhamra
|
Tel: 020 7597 4000
|
|
|
Walbrook PR
Limited
Paul McManus / Alice Woodings / Charlotte
Edgar
|
Tel: 020 7933 8780
or renalytix@walbrookpr.com
Mob: 07980 541 893 /
07407 804 654 / 07884 664 686
|
|
|
CapComm
Partners
Peter DeNardo
|
Tel: 415-389-6400
or investors@renalytix.com
|
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an
in-vitro diagnostics and laboratory services company that is the
global founder and leader in the new field of bioprognosis™ for
kidney health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ROMPPUQUCUPCGAP
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024